Study guide
12.3 Puerperal Infections & Postpartum Mood Disorders
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
12.3 Puerperal Infections & Postpartum Mood Disorders
Key Takeaways Explain This Topic AI
Postpartum endometritis is a polymicrobial ascending infection of the decidua and myometrium; cesarean delivery represents the single most significant risk factor, carrying a 20- to 30-fold increased risk compared to uncomplicated vaginal delivery.
The diagnostic hallmark of endometritis includes fever >=38.0°C (100.4°F) occurring on any two occasions at least 6 hours apart after the first 24 hours postpartum, fundal tenderness, foul-smelling lochia, and leukocytosis; the gold-standard intravenous antibiotic regimen is Clindamycin (900 mg IV q8h) plus Gentamicin (5 mg/kg IV q24h) until afebrile for 24 to 48 hours.
Persistent fever despite 48 to 72 hours of appropriate dual-agent therapy for endometritis mandates adding Ampicillin (2 g IV q6h) for enterococcal coverage and ruling out septic pelvic thrombophlebitis (SPT) or pelvic abscess via pelvic CT imaging.
Postpartum affective disorders exist on a continuum: postpartum blues (50%–80% prevalence, onset days 2–4, self-limiting by 10–14 days, functioning preserved), postpartum depression (PPD, 10%–15% prevalence, insidious onset within 12 months, Edinburgh Postnatal Depression Scale score >=10), and postpartum psychosis (1–2 per 1,000, psychiatric emergency, onset within 2 weeks, infanticide risk ~4%).
First-line pharmacotherapy for postpartum depression in breastfeeding mothers is sertraline (Zoloft), characterized by minimal breast milk transfer and undetectable infant serum concentrations; zuranolone (Zurzuvae, 50 mg daily for 14 days) is an FDA-approved neuroactive steroid GABA-A positive allosteric modulator offering rapid symptom alleviation.
Last updated: October 2026
Puerperal Infections & Postpartum Mood Disorders
Puerperal morbidity encompasses both infectious complications and psychiatric illnesses arising during the postpartum period. Prompt identification of bacterial infection prevents progression to pelvic abscess, septic pelvic thrombophlebitis (SPT), or systemic septic shock, while systematic mood disorder screening protects maternal-infant attachment and prevents catastrophic maternal-infant harm.
Postpartum Endometritis: Pathophysiology & Risk Factor Profile
Postpartum endometritis (endomyometritis) is a polymicrobial infection involving the decidual lining and underlying myometrium. It develops via ascending migration of normal cervicovaginal flora into the warm, blood-rich, traumatized uterine cavity following delivery.
Microbiology: Polymicrobial mixture of aerobic and anaerobic bacteria:
Gram-Positive Aerobes: Group B Streptococcus ( Streptococcus agalactiae ), Enterococcus faecalis, Staphylococcus aureus.
Gram-Negative Aerobes: Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis .
Anaerobes: Bacteroides fragilis , Prevotella species, Peptostreptococcus species, Clostridium species.
Atypical/Other: Mycoplasma hominis , Ureaplasma urealyticum , Group A Streptococcus ( Streptococcus pyogenes —causes fulminant toxic shock with scant odorless lochia).
Primary Risk Factors:
Cesarean delivery is the single greatest risk factor (20- to 30-fold higher risk than vaginal birth in the absence of antibiotic prophylaxis).
Prolonged rupture of membranes (PROM >18–24 hours).
Prolonged labor with frequent digital cervical examinations (>5–6 exams).
Clinical intraamniotic infection (chorioamnionitis) during labor.
Internal fetal/uterine monitoring (fetal spiral electrode, intrauterine pressure catheter).
Manual removal of the placenta or retained placental fragments.
Clinical Presentation & Diagnostic Criteria of Endometritis
Puerperal morbidity is traditionally defined as a temperature >=38.0°C (100.4°F) on any two occasions at least 6 hours apart after the first 24 hours postpartum (mild low-grade elevation in the first 24 hours often reflects dehydration and labor exertion).
Clinical Triad & Diagnostic Features
Fever: Temperature >=38.0°C (frequently spiking to 38.5°–39.5°C).
Uterine Tenderness: Exquisite, disproportionate fundal and paramedrial tenderness elicited upon gentle abdominal palpation.
Abnormal Lochia: Foul-smelling, purulent, cloudy lochial discharge (note: Group A streptococcal endometritis is a critical exception that presents with high fever, rapid toxicity, and scant odorless lochia).
Associated Findings: Maternal tachycardia (>100 bpm), chills, malaise, anorexia, lower abdominal cramping, and leukocytosis (>15,000–25,000/μL with pronounced left shift and immature bandemia).
Gold-Standard Antimicrobial Regimens & Management of Refractory Fever
Intravenous broad-spectrum antimicrobial therapy must be initiated immediately upon clinical diagnosis. Routine endometrial cultures are not required prior to treatment due to unavoidable cervicovaginal contamination.
Gold-Standard First-Line Regimen:
Clindamycin 900 mg IV every 8 hours PLUS Gentamicin 5 mg/kg IV once daily (preferred) or 1.5 mg/kg IV every 8 hours.
Clindamycin provides potent coverage against anaerobes (including Bacteroides ) and Gram-positive cocci; gentamicin covers Gram-negative aerobic bacilli ( E. coli ).
Renal Impairment Modification: Ampicillin-sulbactam 3 g IV every 6 hours or piperacillin-tazobactam 3.375–4.5 g IV every 6 hours serves as an alternative if aminoglycosides are contraindicated.
Treatment Endpoint: Continue IV therapy until the patient is afebrile (<37.8°C) and completely asymptomatic (no fundal tenderness) for 24 to 48 hours . Randomized controlled trials demonstrate that transition to oral antibiotics after successful IV treatment of uncomplicated endometritis is unnecessary and provides no clinical benefit .
Management of Refractory Fever (After 48–72 Hours):
Add Enterococcal Coverage: Add Ampicillin 2 g IV every 6 hours (gentamicin + clindamycin lacks activity against Enterococcus faecalis ).
Rule Out Complications: Perform contrast-enhanced pelvic CT or MRI to detect pelvic abscess, infected hematoma, or Septic Pelvic Thrombophlebitis (SPT) .
Septic Pelvic Thrombophlebitis (SPT): Thrombosis in the ovarian veins or pelvic venous plexus with superimposed bacterial infection. Characterized by persistent spiking fevers "picket-fence pattern" despite triple antibiotics. Treatment: Continue therapeutic broad-spectrum antibiotics and initiate therapeutic anticoagulation (unfractionated or low-molecular-weight heparin); clinical defervescence within 48–72 hours supports the diagnosis.
Surgical Site Infections & Perineal Wound Breakdown
Cesarean Incision SSI: Superficial incisional infection manifests with localized erythema, warmth, induration, and purulent discharge at the Pfannenstiel incision. Treatment requires opening the wound, draining purulence, debridement of devitalized tissue, and moist saline-to-dry gauze dressing changes (or negative-pressure wound therapy), followed by delayed primary closure.
Episiotomy / Laceration Dehiscence: Requires evaluation for necrotizing fasciitis (a surgical emergency characterized by "dishwater" fluid, severe pain out of proportion, skin bullae, crepitus, and systemic toxicity requiring radical surgical debridement). Uninfected dehisced perineal wounds can undergo early surgical repair after the wound base is clean and granulating.
The Postpartum Mood Continuum: Blues vs. Depression vs. Psychosis
Maternal affective disorders represent a spectrum of severity requiring distinct clinical management paradigms:
Diagnostic Entity Prevalence & Onset Core Clinical Features Impact on Daily Functioning Standard Clinical Management
Postpartum Blues ("Baby Blues") 50%–80% of mothers; Onset days 2 to 4 postpartum; peaks day 5 Emotional lability, tearfulness, transient anxiety, irritability, insomnia, fatigue Preserved. Capable of caring for herself and the newborn; no thoughts of self-harm or harming infant Self-limiting; resolves spontaneously within 10 to 14 days . Anticipatory guidance, emotional validation, restorative sleep, partner support.
Postpartum Depression (PPD) 10%–15% of mothers; Onset insidious, 2–12 weeks (up to 12 months) postpartum Persistent dysphoria, severe anhedonia, overwhelming guilt, feelings of failure/worthlessness, sleep disturbance unrelated to infant, panic attacks, impaired bonding, suicidal ideation Significantly Impaired. Difficulty executing activities of daily living and responding to infant cues; disinterest in infant Universal screening (EPDS). Psychotherapy (CBT/IPT) for mild-to-moderate; pharmacotherapy (SSRIs, zuranolone) for moderate-to-severe.
Postpartum Psychosis 1 to 2 per 1,000 births (0.1%–0.2%); Acute onset within first 1 to 2 weeks Bizarre delusions (often focused on infant, e.g., infant is evil/possessed), auditory/visual hallucinations, mania, delirium, gross confusion, depersonalization Total Impairment. Complete break from reality; infanticide risk ~4% , suicide risk ~5% ACUTE MEDICAL EMERGENCY. Immediate psychiatric hospitalization; separate mother from infant; mood stabilizers (lithium), antipsychotics, ECT.
Screening Protocols (EPDS) & Advanced Psychopharmacology
ACOG mandates universal postpartum screening using a validated clinical instrument:
Edinburgh Postnatal Depression Scale (EPDS): A 10-item self-report questionnaire administered at postpartum visits and well-child pediatric checks (1, 2, 4, 6 months).
Score >=10 (or >=12): Warrants clinical diagnostic evaluation and intervention.
Question 10 (Suicidality): Any affirmative answer (>0) regarding self-harm requires immediate safety evaluation and emergent crisis triage.
First-Line SSRI Pharmacotherapy:
Sertraline (Zoloft): The first-line drug of choice during lactation. It has high protein binding (98%) and low milk transfer, producing an infant relative dose (RID) <2% and undetectable infant serum levels.
Paroxetine (Paxil): Also demonstrates low milk transfer, but carries withdrawal and sedating properties; sertraline is preferred.
Fluoxetine (Prozac): Has a long elimination half-life and active metabolite (norfluoxetine), resulting in higher infant serum accumulation and RID (~5%–9%); less preferred for initiation during lactation.
Zuranolone (Zurzuvae): An FDA-approved oral neuroactive steroid and positive allosteric modulator of GABA-A receptors. Dosed at 50 mg orally once daily in the evening with a fat-containing meal for 14 days . It provides rapid symptom reduction within 3 to 15 days. Patients must be counseled regarding sedation, driving impairment, and using effective contraception during treatment.